Celesio

• EBITDA above prior-year level at 139.9 million euro (plus 5.1 per cent)
• Operational Excellence Programme for the stabilisation of earnings is beginning to take effect
• Sales process for Movianto, Pharmexx and the DocMorris mail-order pharmacy initiated

• Takeover of the remaining 49.9 per cent in Panpharma
• Promising growth opportunities in Brazil due to positive market development and consolidation

• Result to be stabilised in 2012 at the level of the previous year. Operational Excellence Programme will contribute significantly towards this
• Sales process for Movianto, Pharmexx and DocMorris mail-order business initiated
• 2011: Earnings forecast with 578.3 million euro EBITDA before one-off effects achieved

Stuttgart, 20 December 2011. Today the Supervisory Board of Celesio AG appointed Marion Helmes the new Chief Financial Officer of the company, effective from 1 January 2012. In this role, she will be responsible for Finance and Treasury, Controlling, Accounting, Tax, Human Resources and IT. Most recently, Marion Helmes was member of the management board (CFO) at Q-Cells AG, Bitterfeld-Wolfen. At Celesio, she is replacing Christian Holzherr, who left the company as of 30 November 2011 on his own initiative.

• Pharmaceutical wholesale is set to expand expertise across complete logistics chain including specialist distribution
• With innovative service and shop concepts Celesio aims to become partner of first choice for pharmacies in Europe
• Good opportunities for expansion in growth markets such as Brazil, Latin America and the Middle East
• Management board examining sale of Manufacturer Solutions
• Operational Excellence Programme will sustainably increase competitiveness and secure turnaround in earnings already in 2012
• Realignment assures return to sustainably profitable growth

• Majority shareholding of 60 per cent in Oncoprod Group, a specialty pharmaceutical distributor with a focus on highly complex medicines, e.g. against cancer
• Building up a leading position in the growth market Brazil

• Celesio and Medco mutually agree to terminate the collaboration
• Medco will assume full ownership and operational control of the pan-European healthcare venture; delivering new healthcare solutions
• Celesio will continue with its existing activities to improve healthcare for patients with chronic or complex diseases

• Revenue virtually stable at 11.5 billion euro
• EBITDA decreases by 16.3 per cent to 271.7 million euro
• Extraordinary impairment write-offs of 116.3 million euro
• Realignment of Lloydspharmacy started